Silverarc Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Silverarc Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.2M	Buy	693,600 +373,600	+117%	+$7.77M	1.58%	21
2026 Q1	$7.48M	Buy	+320,000	New	+$6.95M	0.76%	34
2025 Q4	–	Sell	-50,000	Closed	-$770K	–	94
2025 Q3	$770K	Hold	50,000	–	–	0.1%	72
2025 Q2	$468K	Buy	+50,000	New	+$550K	0.09%	57
2025 Q1	–	Sell	-172,400	Closed	-$2.28M	–	80
2024 Q4	$2.28M	Buy	+172,400	New	+$2.95M	0.5%	43

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Silverarc Capital Management's SNDX Position: Q2 2026 in Review

Silverarc Capital Management increased its Syndax Pharmaceuticals (SNDX) stake by 37% in Q2 2026, buying an estimated $6.77M and bringing the position to 1,214,390 shares worth $26.5M. The position accounts for 2.76% of the portfolio, ranked #10.

Silverarc Capital Management first reported a position in SNDX in Q4 2020 and has held it in 17 quarters since. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Silverarc Capital Management held 1,214,390 shares of Syndax Pharmaceuticals worth $26.5M as of Q2 2026.
Silverarc Capital Management bought 325,403 Syndax Pharmaceuticals shares in Q2 2026, an estimated $6.77M.
Syndax Pharmaceuticals made up 2.76% of Silverarc Capital Management's portfolio in Q2 2026, its #10 holding.
Silverarc Capital Management first reported a position in Syndax Pharmaceuticals in Q4 2020 and has held it in 17 quarters since.
243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.